NVX-412, a new oncology drug candidate, induces S-phase arrest and DNA damage in cancer cells in a p53-independent manner.

Publikationen als Autor:in / Herausgeber:in der Vetmeduni

Rütgen, Barbara

Schlagwörter

Antineoplastic Agents/chemistry; Antineoplastic Agents/pharmacology*; Antineoplastic Agents/therapeutic use*; Cell Line, Tumor; Cell Shape/drug effects; Cell Size/drug effects; DNA Damage*; DNA Replication/drug effects; Drug Screening Assays, Antitumor; Humans; Hydrazines/chemistry; Hydrazines/pharmacology*; Hydrazines/therapeutic use*; Inhibitory Concentration 50; Neoplasms/drug therapy*; Neoplasms/pathology*; Phosphorylation/drug effects; Quinoxalines/chemistry; Quinoxalines/pharmacology*; Quinoxalines/therapeutic use*; S Phase Cell Cycle Checkpoints/drug effects*; Tumor Markers, Biological/metabolism; Tumor Suppressor Protein p53/metabolism;

ISSN/eISSN

1932-6203 -

WoS ID

WOS:000308788700077

Titel des Sammelwerks

PLOS ONE;